7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Loop combined endoscopic clip and cyanoacrylate injection to treat severe gastric varices with spleno-renal shunt

      brief-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Endoscopic cyanoacrylate injection has been successfully applied in the management of gastric variceal bleeding and is recommended as the first line of treatment in China. 1 Systemic embolism is one of the most severe and fatal adverse events associated with cyanoacrylate injection when used to treat severe gastric varices with a spleno-renal or gastric-renal shunt. 2 Here, we report a case in which we used a new method to obstruct severely isolated gastric varices with a massive spleno-renal shunt and reduce embolic risk. A 53-year-old woman who had experienced GI hemorrhage weeks prior and had undergone subtotal gastrectomy and Billroth II anastomosis for obscure hemorrhagic shock 18 years earlier was admitted to our hospital. Physical examination showed that the spleen was located 4 cm below the rib. Laboratory tests showed that red blood cell, white blood cell, and platelet counts were all decreased. CT showed a large gastric varix (yellow arrow) with a massive spleno-renal shunt (green arrow) (Fig. 1), and upper endoscopy revealed a gastric fundal varix approximately 12 mm in diameter (Fig. 2). The patient refused therapy other than prophylactic endoscopic therapy for recurrent bleeding. Figure 1 CT scan showed a large gastric fundal varix (yellow arrow) with a massive spleno-renal shunt (green arrow). Figure 2 Upper endoscopy revealed a gastric fundal varix measuring approximately 12 mm. A clip was placed in the middle of the varix for 2 purposes: to reduce partial blood flow and to serve as a fixed point to help the loop encircle the afferent vein. We contracted the loop gradually and slowed suction simultaneously to partially obstruct further blood flow. After releasing the loop, we injected a mixture of 2 mL lauromacrogol, 1 mL cyanoacrylate, and 2 mL sodium chloride solution into the ligated vein to stop further blood flow. We injected the mixture into the afferent vein 3 times and then injected it into the efferent vein to thoroughly block blood flow. One week later, endoscopy showed that the gastric fundal varix had been obstructed successfully, and a CT scan showed that the gastric varix (yellow arrow) and spleno-renal shunt (green arrow) had also lessened (Fig. 3). Moreover, no systemic embolism occurred. There was no bleeding during the half-year follow-up. At 3 and 6 months later, endoscopy (Figs. 4 and 5) and a CT scan (Fig. 6) showed that the fundal varix had gradually disappeared. Figure 3 One week later, CT scan showed the obstructed gastric varix (yellow arrow) and the spleno-renal shunt (green arrow). Figure 4 Upper endoscopy revealed the fundal varix was coagulated 3 months later. Figure 5 Endoscopy showed the fundal varix had disappeared gradually by 6 months later. Figure 6 CT scan showed fundal varix had disappeared (yellow arrow) by 6 months later. In this case, the novel method of cyanoacrylate injection therapy assisted by loop-combined endoscopic clipping successfully prevented recurrent hemorrhage and reduced the amount of cyanoacrylate used to help avoid fatal embolism. In addition, this method was low cost. Compared with transjugular intrahepatic portosystemic shunt (TIPS) and balloon-occluded retrograde transvenous obliteration (BRTO), which are popular therapies in East Asia, our new method does not need to strictly select patients and can avoid radioactive damage to operators. TIPS and BRTO are both interventional radiologic treatments, and appropriate patient selection is critical; TIPS is rarely used in patients with Child–Pugh class C and those with advanced liver disease, and BRTO is technically feasible only in patients with a known gastrorenal shunt, accounting for only 85% of patients with gastric varices. 3 This suggests that the novel method could be superior in safety to cyanoacrylate injection alone and could be more easily performed than TIPS and BRTO. In addition, it could be less expensive than other invasive therapies. Escorsell et al 4 reported that TIPS was twice as expensive as endoscopic treatment. In China, surgery for bleeding esophagogastric varices is costly. There are some limitations to our new method. The gastric varices must be large enough and protrude out of the stomach lumen so that the loop can encircle them; otherwise, the loop cannot be used (Video 1, available online at www.VideoGIE.org). Disclosure All authors disclosed no financial relationships.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: found
          • Article: not found

          A pathophysiologic, gastroenterologic, and radiologic approach to the management of gastric varices.

          Gastric varices (GV) occur in 20% of patients with portal hypertension either in isolation or in combination with esophageal varices (EV). There is no consensus for optimum treatment of GV and because they comprise an inhomogeneous entity, accurate classification is vital to determine the appropriate management. Gastroesophageal varices (GOV) are classified as GOV1 (EV extending down to cardia or lesser curve) or GOV2 (esophageal and fundal varices). Isolated gastric varices (IGV) may be located in the fundus (IGV1) or elsewhere in the stomach (IGV2). GV possibly bleed less frequently than EV, but GV bleeding is typically difficult to control, associated with a high risk for rebleeding, and high mortality. Fundal varices, large GV (>5 mm), presence of a red spot, and Child's C liver status are associated with a high risk for bleeding. GOV1 have a much lower risk for bleeding. A portosystemic pressure gradient of > or =12 mm Hg is not necessary for GV bleeding, probably related to the high frequency of spontaneous gastrorenal shunts in these patients. GOV1 should be treated as for EV. First-line treatment of bleeding fundal varices is endoscopic variceal obturation. TIPS is currently second-line acute treatment and is used for prevention of rebleeding. The role of some newer interventional radiologic techniques requires further appraisal. This review describes the pathophysiology, diagnosis, natural history, endoscopic, and interventional radiologic treatment options for GV.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Management of gastric varices.

            According to their location, gastric varices (GV) are classified as gastroesophageal varices and isolated gastric varices. This review will mainly focus on those GV located in the fundus of the stomach (isolated gastric varices 1 and gastroesophageal varices 2). The 1-year risk of GV bleeding has been reported to be around 10%-16%. Size of GV, presence of red signs, and the degree of liver dysfunction are independent predictors of bleeding. Limited data suggest that tissue adhesives, mainly cyanoacrylate (CA), may be effective and better than propranolol in preventing bleeding from GV. General management of acute GV bleeding must be similar to that of esophageal variceal bleeding, including prophylactic antibiotics, a careful replacement of volemia, and early administration of vasoactive drugs. Small sample-sized randomized controlled trials have shown that tissue adhesives are the therapy of choice for acute GV bleeding. In treatment failures, transjugular intrahepatic portosystemic shunt (TIPS) is considered the treatment of choice. After initial hemostasis, repeated sessions with CA injections along with nonselective beta-blockers are recommended as secondary prophylaxis; whether CA is superior to TIPS in this scenario is not completely clear. Balloon-occluded retrograde transvenous obliteration (BRTO) has been introduced as a new method to treat GV. BRTO is also effective and has the potential benefit of increasing portal hepatic blood flow and therefore may be an alternative for patients who may not tolerate TIPS. However, BRTO obliterates spontaneous portosystemic shunts, potentially aggravating portal hypertension and its related complications. The role of BRTO in the management of acute GV bleeding is promising but merits further evaluation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial.

              Prevention of variceal rebleeding is mandatory in cirrhotic patients. We compared the efficacy, safety, and cost of transjugular intrahepatic portosystemic shunt (TIPS) versus pharmacologic therapy in preventing variceal rebleeding in patients with advanced cirrhosis. A total of 91 Child-Pugh class B/C cirrhotic patients surviving their first episode of variceal bleeding were randomized to receive TIPS (n = 47) or drug therapy (propranolol + isosorbide-5-mononitrate) (n = 44) to prevent variceal rebleeding. Mean follow-up was 15 months. Rebleeding occurred in 6 (13%) TIPS-treated patients versus 17 (39%) drug-treated patients (P =.007). The 2-year rebleeding probability was 13% versus 49% (P =.01). A similar number of reinterventions were required in the 2 groups; these were mainly angioplasty +/- restenting in the TIPS group (90 of 98) and endoscopic therapy for rebleeding in the medical group (45 of 62) (not significant). Encephalopathy was more frequent in TIPS than in drug-treated patients (38% vs. 14%, P =.007). Child-Pugh class improved more frequently in drug-treated than in TIPS-treated patients (72% vs. 45%; P =.04). The 2-year survival probability was identical (72%). The identified cost of therapy was double for TIPS-treated patients. In summary, medical therapy was less effective than TIPS in preventing rebleeding. However, it caused less encephalopathy, identical survival, and more frequent improvement in Child-Pugh class with lower costs than TIPS in high-risk cirrhotic patients. This suggests that TIPS should not be used as a first-line treatment, but as a rescue for failures of medical/endoscopic treatments (first-option therapies).
                Bookmark

                Author and article information

                Journal
                VideoGIE
                VideoGIE
                VideoGIE
                Elsevier
                2468-4481
                26 August 2020
                December 2020
                26 August 2020
                : 5
                : 12
                : 652-654
                Affiliations
                [1]Department of Gastroenterology and Hepatology, Beijing Ditan Hospital, Capital Medical University, Beijing, China
                Article
                S2468-4481(20)30246-0
                10.1016/j.vgie.2020.07.020
                7730510
                14e93dc1-b58a-442b-b7cc-918f5082875d
                © 2020 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                Categories
                Video Case Report

                brto, balloon-occluded retrograde transvenous obliteration,tips, transjugular intrahepatic portosystemic shunt

                Comments

                Comment on this article